Solventum Corp Q3 FY2024 earnings call

Management Statement and Operational Highlights:

• Phase 1: Progressed with culture shaping, new leaders gelling, and advancement of the Solventum Way restructuring project to create a flexible and decentralized structure.
• Phase 2: Focused on long-range profitable growth, with recent product launches including MedSurg's V.A.C. Peel and Place dressing, Dental's Clinpro Clear Fluoride Treatment, Health Information Systems' AI-driven revenue integrity solution, and Purification and Filtration's Harvest RC family product.
• Phase 3: Actively assessing portfolio optimization by evaluating market and business alignment.

Segment Performance:

• MedSurg: Delivered $1.2 billion of sales, a 1% organic growth. It is the largest segment.
• Dental: Generated $313 million of revenue, a decrease of 3.9% due to tough market conditions and year-over-year comparisons.
• Health Information Systems: Contributed $326 million of revenue, a 1.5% increase, benefiting from growth in revenue cycle management but facing challenges in clinical productivity solutions.
• Purification and Filtration: Delivered $238 million of sales, a 0.3% decline, impacted by declines in drinking water filtration and dialysis membranes but offset by better performance in bioprocessing filtration and industrial filtration capacity.

Guidance:

• Raised full-year organic growth rate to the upper half of the prior guidance range of flat to 1%.
• Increased adjusted EPS guidance to $6.50 to $6.65 and free cash flow guidance to $750 million to $850 million.
• Q4 EPS guidance is $1.22 to $1.37, impacted by reversing one-time gross margin benefits and continued investments.

Risks:

• ERP transition challenges with potential bumps and gaps.
• Market softness affecting segments like Dental.
• Potential headwinds from SKU rationalization Wave 2.
• FX headwinds in Q4.

Q: Travis Steed asked about Q4 EPS guidance and 2025 outlook.

A: Wayde McMillan said Q4 EPS is impacted by reversing one-time gross margin benefits, continued investments, and FX headwinds. 2025 guidance not provided yet with various factors like annualization of costs, 3M supply markup, and SKU rationalization.

Q: Patrick Wood asked about TSAs timeline and dental market transition.

A: Wayde McMillan said no update on TSA timelines. Bryan Hanson said negative pressure wound therapy has separate segments with Prevena (single-use) growing and traditional slower growth with Peel and Place product as a growth mechanism.

Q: Vikramjeet Chopra asked about SKU rationalization project.

A: Wayde McMillan said Wave 1 executed with little impact, Wave 2 under review. Bryan Hanson said portfolio management decisions made with shareholder value in mind.

Q: David Roman asked about gross margin drivers.

A: Wayde McMillan explained Q2 headwinds reversing in Q3, Q3 one-time benefits reversing in Q4, and expected margin below 56%.

Q: Rick Wise asked about MedSurg growth and ERP transition.

A: Bryan Hanson said MedSurg sees improvement with talent, commercial rigor, and new launches. Wayde McMillan said ERP implemented in 4 countries with progress and challenges.

Q: Ryan Zimmerman asked about China exposure and Purification business.

A: Bryan Hanson said China exposure is ~5% and not major impact from tariffs. Wayde McMillan said no falloff in dialysis filtration demand.

Q: Jason Bednar asked about Dental pricing and portfolio divestiture.

A: Bryan Hanson said Dental pricing neutral, and portfolio divestiture considerations involve 3M clearance and shareholder value. Wayde McMillan said Dental volumes starting to improve.

Q: Christopher Senyek asked about Health Information Systems growth.

A: Bryan Hanson said revenue cycle management steady, clinical productivity solutions challenged, and data integrity solution as a focus.

Q: Chris Senyek asked about FX and revenue cost mix.

A: Wayde McMillan said FX guidance and revenue cost mix based on diversification and manufacturing footprint.

Q: David Roman asked about CapEx.

A: Bryan Hanson and Wayde McMillan discussed CapEx for capacity investments in purification and filtration, and focus on growth driver-related CapEx with separation and organic growth investments.